 |
|
|
| |
NIRMATRELVIR/RITONAVIR VERSUS PLACEBO IN UNVACCINATED AND VACCINATED HIGH-RISK PATIENTS
|
| |
| |
ID Week 2023 oct 14
Heidi Leister-Tebbe,1 Weihang Bao,2 Robert Fountaine,3 Mary Lynn Baniecki,4 Victoria M. Hendrick,5 Wayne Wisemandle,6 Jennifer Hammond,1 James M. Rusnak7
1Pfizer Research & Development, Pfizer Inc, Collegeville, PA, USA; 2Pfizer Research & Development, Pfizer Inc, New York, NY, USA; 3Pfizer Research & Development, Pfizer Inc, Groton, CT, USA; 4Early Clinical Development, Pfizer Inc, Cambridge, MA, USA; 5Medical and Safety, Pfizer, Sandwich, UK; 6Pfizer Research & Development, Pfizer Inc, Lake Forest, IL, USA; 7Pfizer Research & Development, Pfizer Inc, Tampa, FL, USA
|
| |
|
|
|
|
|
